Forecast horizon — calibration-scored at resolution.
By 2028, 10-year survival data from CheckMate-067 will show a plateau ≥40% in the combination arm.
Your probability this resolves TRUE
0% (impossible)
50%
100% (certain)
Proper-scoring-rule preview
Your position is kept on this device until you sign in.
Evidence stream
2 events · 1 snapshot
posterior drift
71% → 71% (0pp · 1 point)
Registry data
Apr 18, 2026
Peer-reviewed paper
Apr 18, 2026
Expert reactions · 0
Sign in to post a take, cite a related claim, or flag a methodological concern.
No reactions yet. Be the first expert to post a take, cite a related claim, or flag a methodological concern.
Source publication
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al. · New England Journal of Medicine · 2017
· openalex W2753432434
Semantically related
Nearest claims in the expert-corpus vector space. Ordered by cosine distance — lower is closer.
0.1448
Recent follow-up analyses of CheckMate-067 are confirming the original effect size in real-world data.
0.1650
The CheckMate-067 trial's stated primary conclusion — Nivolumab + ipilimumab combination yields superior long-term survival in advanced melanoma vs. either monotherapy. — replicates in independent cohorts.
0.2063
Recent follow-up analyses of KEYNOTE-522 are confirming the original effect size in real-world data.
0.2084
Recent follow-up analyses of KEYNOTE-189 are confirming the original effect size in real-world data.
0.2153
Pembrolizumab's PFS and OS benefit over ipilimumab in advanced melanoma will be maintained at longer follow-up beyond the median 7.9-month observation period reported in this trial.
0.2200
By 2028, pembrolizumab-containing regimens will be first-line for >90% of eligible metastatic non-squamous NSCLC in US practice.